**SUPPLEMENTARY DATA**

**Supplementary Table 1.** The main characteristic of the eligible studies.



**Supplementary Figure 1.** Risk of bias assessment using modified Downs and Black checklist.



**Supplementary Figure 2.** Viral clearance of SARS-CoV-2 in symptomatic subpopulations. HCQ ± AZI: the use of hydroxychloroquine with or without azithromycin; HCQ alone: the use of hydroxychloroquine without azithromycin; HCQ + AZI: combination of hydroxychloroquine and azithromycin; CI: confidence interval.



**Supplementary Figure 3.** Viral clearance of SARS-CoV-2 in adult subpopulations. HCQ ± AZI: the use of hydroxychloroquine with or without azithromycin; HCQ alone: the use of hydroxychloroquine without azithromycin; HCQ + AZI: combination of hydroxychloroquine and azithromycin; CI: confidence interval.



**Supplementary Figure 4.** Publication bias.

